Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Investing.com -- CytomX Therapeutics Inc (NASDAQ:CTMX) stock dropped 4.3% Monday after the company disclosed a patient death in its Phase 1 study of CX-2051, its experimental cancer treatment.
The biotechnology company reported a Grade 5 (fatal) treatment-related acute kidney injury in a patient with a complex medical history, including having a solitary kidney. The death was believed to be secondary to nausea, vomiting, and diarrhea, according to a company update.
CytomX became aware of the event on July 11 and reported it to the FDA on July 18 in accordance with regulatory requirements. Despite the fatality, the company’s Safety Review Committee met on July 14 and supported continued study execution and enrollment.
"Since our initial data disclosure in May 2025, Phase 1 enrollment has been rapid and is substantially complete. We are on track to provide a data update in the first quarter of 2026," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX.
The company, which specializes in masked, conditionally activated biologics, noted that the CX-2051 dose expansion cohorts at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses (administered every three weeks) have each enrolled approximately 20 patients as planned.
CytomX indicated that the CTMX-2051-101 study is continuing, with a Phase 1 data update expected by the first quarter of 2026. The company emphasized that patient safety remains its top priority as it advances CX-2051 for the treatment of colorectal cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.